Shanghai Medicilon Inc.

  On July 4 th , the 2024 International Pharmaceutical Services Industry Innovation and Development Conference, along with the 9 th   Summit for China Pharmaceutical R&D Innovation, was grandly held at the Xiongan Convention and Exhibition Center.  At the conference, the highly anticipated "2024 China Pharmaceutical R&D Strength Ranking" was announced.  Shanghai Medicilon Inc. (Medicilon) stood out among hundreds of pharmaceutical enterprises and was honored with the " Top 20 Chinese R&D CRO Enterprises in 2024" award. About the Top 20 Chinese R&D CRO Enterprises in 2024 The "2024 China Pharmaceutical R&D Strength Ranking" is selected by the Organizing Committee of the China Pharmaceutical R&D Innovation Summit and the Expert Committee of the 2024 China Pharmaceutical R&D Strength Ranking. It aims to uncover and drive innovative forces in pharmaceutical R&D, encourage and recognize enterprises making significant contributio...

On May 9th, the "2024 Top 100 Future Healthcare" series rankings were officially unveiled. Medicilon successfully made it onto the list and was awarded the "Best Client Satisfaction Pharmaceutical CRO" due to its outstanding market performance, human resources, knowledge resources, and essential partnership resources. The "2024 Top 100 Future Healthcare" list was jointly launched by vbdata.cn, VB100, and VCBeat Research, aiming to select truly representative Chinese innovative medical practitioners who embody the future of healthcare and drive the innovative transformation process in the health and medical industry. This selection process, with a strict and fair evaluation mechanism, combines multiple stages including independent company applications, professional evaluations, cross-evaluations by supporting organizations, and final review by an expert committee. It focuses on the growth and annual performance of candidate companies across 17 secondary in...

  On June 29, the 9th China Bio-Pharma Innovation Cooperation Conference (BIO-PHARM2023) and the 2023 China Biopharmaceutical Industry Value List Awards Ceremony were grandly opened in Suzhou.  Shanghai Medicilon Inc. was listed in the "Top 10 Most Influential CRO Enterprises" of the 2023 China Biopharmaceutical Industry Value List by virtue of its excellent R&D capabilities and outstanding innovative service platform. The Huayi List - 2023 China Biopharmaceutical Industry Value List is established by the Huayi Research Institute through selection, aiming to discover innovative companies with real industry influence and growth potential in the field of biopharmaceutical.  Huayi Research Institute is one of the few medical investment research institutes in China, and is also the definer of the China medical investment.  The value list consists of five series of selections:  antibody drugs , innovative therapies, biotechnology, CRO, and  CDMO , and the se...

  On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released and grandly awarded at the "2023 Conference on High Quality Development of Healthcare Industry & the Eight Summit for China Pharmaceutical R&D Innovation"!  Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List. This is also the 4th consecutive year that Medicilon has won this honor! The selection of "Top 20 Chinese R&D CRO Enterprises in 2023" list is strictly based on the 10 indicators such as company's annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, number of employees, number of employees growth, brand popularity and leader in subdivided fields.  The list represents the highest level of  China's pharmaceutical CRO/CDMO industry .

  On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released and grandly awarded at the "2023 Conference on High Quality Development of Healthcare Industry & the Eight Summit for China Pharmaceutical R&D Innovation"!  Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List. This is also the 4th consecutive year that Medicilon has won this honor! The selection of "Top 20 Chinese R&D CRO Enterprises in 2023" list is strictly based on the 10 indicators such as company's annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, number of employees, number of employees growth, brand popularity and leader in subdivided fields.  The list represents the highest level of  China's pharmaceutical CRO/CDMO industry .

  ❖  Contract Research Organization CRO Contract Research Organization, referred to as CRO, mainly provides drug discovery, preclinical research, clinical trials and other new drug R&D contract research services for multinational pharmaceutical companies and pharmaceutical companies. At present, biomedical R&D outsourcing has gradually become an indispensable link in the pharmaceutical industry chain and plays an important role in the industrial structure. ❖      Medicilon’s Preclinical Research Services Medicilon is a Preclinical Research Outsourcing (CRO) company. With our more than 10 years experience on preclinical research services, we dedicated to provide our clients with customized preclinical services program in drug metabolism, pharmacokinetics, efficacy studies, and toxicology. We provide our clients a high-quality data and rapid turnaround time to support their drug development, preclinical studies and clinical research and to help them to sel...

  The   yeast “two hybrid”   or “interaction trap” assay, is a technique used to study protein-protein interactions, which are critical in virtually all cellular processes. The study of protein-protein interactions can be divided into three major parts: • Identification of binding proteins • Characterization of known interactions • Potential to manipulate such interactions This technology is based on the fact that the activating domain (AD) and binding domain (BD) of a transcription factor can be separated and still function when they get into close proximity. Y2H screening is therefore designed to use a BD fused bait protein to screen against a library of AD fused prey proteins. The bait is usually a known protein that the researcher tries to identify new interacting partners with. The prey is usually a library of proteins to be screened from. When the bait protein binds to the prey protein, transcription of the specially designed reporter genes occurs and allows selecti...

  In 2020, a global outbreak of the new crown epidemic disrupted the business activities of almost all companies, and the drug R&D and production of pharmaceutical companies was no exception. As a   CRO/CDMO company   serving pharmaceutical companies, its market share and global ranking have also changed when the global market order is chaotic. 　　 2021 Global CRO Ranking TOP10 Rank Company 2020 Revenue / Billion of dollars Compare with 2019 Staff in 2020 1 LabCorp 139.8 21.00% 75000 2 IQVIA 113.6 2.40% 70000 3 ICON+PRA 59.8 1.90% 35000 4 Lonza 49.5 12.50% 14000 5 PPD 46.8 16.10% 26000 6 Syneos 44.2 -5.60% 25000 7 Wuxi 32.6 31.40% 32000 8 Catalent 30.9 22.90% 15000 9 Charles River 29.2 11.50% 17000 10 Paraxel 25.0 / 19000 Note: ①This list covers CRO in a broad sense, and its business areas cover pre-clinical research, clinical trials, pharmaceutical development, and commissioned production of raw materials and drugs (CDMO and CMO) related to new drug research and devel...

  On September 10, 2020, the “2020 China Pharmaceutical and Health Industry Development Conference and the 4th China Pharmaceutical R&D Innovation Summit (PDI)” announced the “2020 China   Top 20 R&D CRO Companies ” (hereinafter referred to as “R&D CRO List”). Since 2015, the domestic pharmaceutical industry policy reform has accelerated, especially after my country joined ICH in 2017, domestic pharmaceutical companies have accelerated the transformation and upgrading from generic drugs to the combination of generic drugs. The demand side of domestic and foreign outsourcing services is accelerating, and the dividends of innovation and upgrading in the domestic pharmaceutical market are gradually emerging. Some traditional offshore outsourcing companies have begun to attach importance to the expansion of domestic business, and the proportion of onshore outsourcing business in the overall business structure has begun to increase.        ...